155 related articles for article (PubMed ID: 19787152)
1. Neonatal screening for cystic fibrosis in São Paulo State, Brazil: a pilot study.
Rodrigues R; Magalhaes PK; Fernandes MI; Gabetta CS; Ribeiro AF; Pedro KP; Valdetaro F; Santos JL; Souza RM; Pazin Filho A; Maciel LM
Braz J Med Biol Res; 2009 Oct; 42(10):973-8. PubMed ID: 19787152
[TBL] [Abstract][Full Text] [Related]
2. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
3. The first five-year evaluation of cystic fibrosis neonatal screening program in São Paulo State, Brazil.
Maciel LMZ; Magalhães PKR; Ciampo IRLD; Sousa MLB; Fernandes MIM; Sawamura R; Bittar RR; Molfetta GA; Silva Júnior WAD
Cad Saude Publica; 2020; 36(10):e00049719. PubMed ID: 33111836
[TBL] [Abstract][Full Text] [Related]
4. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
5. Pilot study for cystic fibrosis neonatal screening: the Cuban experience.
Castells EM; Sánchez A; Frómeta A; Mokdse Y; Ozunas N; Licourt T; Arteaga AL; Silva E; Collazo T; Rodríguez F; Martín O; Espinosa M; Del Río L; Pérez PL; Morejón G; Almira C; Núñez Z; Melchor A; González EC
Clin Chem Lab Med; 2020 Oct; 58(11):1857-1864. PubMed ID: 32352395
[TBL] [Abstract][Full Text] [Related]
6. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
7. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers.
Ramasli Gursoy T; Asfuroglu P; Sismanlar Eyuboglu T; Aslan AT; Yilmaz AI; Unal G; Kibar BS; Pekcan S; Hangul M; Kose M; Budakoglu II; Acican D
Eur J Pediatr; 2023 Mar; 182(3):1067-1076. PubMed ID: 36565324
[TBL] [Abstract][Full Text] [Related]
9. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
11. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis.
Sarles J; Barthellemy S; Férec C; Iovanna J; Roussey M; Farriaux JP; Toutain A; Berthelot J; Maurin N; Codet JP; Berthézène P; Dagorn JC
Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F118-22. PubMed ID: 10325788
[TBL] [Abstract][Full Text] [Related]
12. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
[TBL] [Abstract][Full Text] [Related]
13. Newborn screening for cystic fibrosis in Switzerland--consequences after analysis of a 4 months pilot study.
Torresani T; Fingerhut R; Rueegg CS; Gallati S; Kuehni CE; Baumgartner MR; Barben J;
J Cyst Fibros; 2013 Dec; 12(6):667-74. PubMed ID: 23712087
[TBL] [Abstract][Full Text] [Related]
14. Newborn screening for cystic fibrosis in Serbia: a pilot study.
Radivojevic D; Sovtic A; Minic P; Grkovic S; Guc-Scekic M; Lalic T; Miskovic M
Pediatr Int; 2013 Apr; 55(2):181-4. PubMed ID: 23163630
[TBL] [Abstract][Full Text] [Related]
15. Initial regional evaluation of the Cystic Fibrosis Newborn Screening Program: data from the Mediterranean coast of Turkey.
Başaran AE; Başaran A; Kocacik DF; Alper Ö; Acican D; Bingöl A
Turk J Med Sci; 2019 Dec; 49(6):1655-1661. PubMed ID: 31655510
[TBL] [Abstract][Full Text] [Related]
16. [Implementation of the neonatal cystic fibrosis screening program in Switzerland: beginning January 2011].
Mornand A; Barben J; Hafen G
Rev Med Suisse; 2011 Feb; 7(283):456, 458-60. PubMed ID: 21452515
[TBL] [Abstract][Full Text] [Related]
17. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
[TBL] [Abstract][Full Text] [Related]
18. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
[TBL] [Abstract][Full Text] [Related]
19. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
20. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
